Sarah M. Berger

Sarah M. Berger

Auto-generated profile, based on publicly available information

Sarah M. Berger

Center for Virology, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
MDMatthias Diebold
Matthias Diebold
HVHannes Vietzen
Hannes Vietzen
AHAndreas Heinzel
Andreas Heinzel
SHSusanne Haindl
Susanne Haindl
CHCarsten T. Herz
Carsten T. Herz
GBGeorg A. Böhmig
Georg A. Böhmig
Antibody-mediated rejection (ABMR) is a leading cause of graft failure. Emerging evidence suggests a significant contribution of natural killer (NK) cells to microvascular inflammation (MVI). We investigated the influence of genetically determined NK cell functionality on ABMR development and activity. The study included 86 kidney transplant recipients subjected to systematic biopsies triggered by donor-specific antibody detection. We performed killer immunoglobulin-like receptor typing to predict missing self and genotyped polymorphisms determining NK cell functionality (FCGR3AV/F158 [rs396991], KLRC2wt/del, KLRK1HNK/LNK [rs1049174], rs9916629-C/T). Forty-four patients had ABMR with considerable MVI and elevated NK cell transcripts. Missing self was not related to MVI. Only KLRC2wt/wt showed an association (MVI score: 2 [median; interquartile range: 0-3] versus 0 [0-1] in KLRC2wt/del recipients; p=0.001) and remained significant in a proportional odds multivariable model (odds ratio [OR]: 7.84, 95% confidence interval [CI]: 2.37-30.47, p=0.001). A sum score incorporating all polymorphisms and missing self did not outperform a score including only KLRC2 and FCGR3A variants, which were predictive in univariable analysis. NK cell genetics did not affect graft functional decline and survival. In conclusion, a functional KLRC2 polymorphism emerged as an independent determinant of ABMR activity, without a considerable contribution of missing self and other NK cell gene polymorphisms.

14 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
HVHannes Vietzen
Hannes Vietzen
LKLaura M. Kühner
Laura M. Kühner
SBSarah M. Berger
Sarah M. Berger
MPMarkus Ponleitner
Markus Ponleitner
MGMarianne Graninger
Marianne Graninger
EPElisabeth Puchhammer-Stöckl
Elisabeth Puchhammer-Stöckl
Multiple sclerosis (MS) is an immune-mediated demyelinating disease. Epstein-Barr virus (EBV) encodes for the EBNA-1381-452 region that induces autoreactive antibody responses, which are likely critically involved in MS pathogenesis. Here we investigate whether these EBNA-1381-452-specific antibodies can serve as a biomarker to identify at-risk individuals for MS. We quantify EBNA-1381-452-specific antibody titers from 324 relapsing-remitting MS patients and 324 matched controls in longitudinal follow-up plasma samples, starting from the individual’s EBV-seroconversion. In MS patients, significantly elevated EBNA-1381-452-specific IgG titers are identified that are increased already as early as nine months after EBV-seroconversion (OR:5.7; 95% CI: 4.1-8.1; P < 0.0001) and a median 5.4 years prior to MS diagnosis. Especially, the presence of continuously high EBNA-1381-452-specific antibody titers is associated with a more rapid MS diagnosis after EBV-seroconversion (P < 0.0001). Thus, the quantification of EBNA-1381-452-specific IgG antibody levels may provide a prognostic biomarker to determine the individual’s risk for the diagnosis of MS.

1 October 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
HVHannes Vietzen
Hannes Vietzen
EWEmmanuelle L. Waubant
Emmanuelle L. Waubant
TCT. Charles Casper
T. Charles Casper
LBLeslie A. Benson
Leslie A. Benson
TCTanuja Chitnis
Tanuja Chitnis
TBThomas Berger
Thomas Berger
Multiple sclerosis (MS) is an autoinflammatory disease of the central nervous system (CNS). Epstein–Barr virus (EBV) encodes for EBNA-1 381-452 , which induces autoreactive immune responses against distinct CNS derived proteins (GlialCAM 370-389 , CRYAB 2-21 , MBP 205-224 , ANO2 135-154 ). Although EBV infection is considered essential for MS development, CNS-specific autoimmune responses may also be present in putatively EBV EBNA-1-seronegative patients, warranting further investigation. We studied 548 EBV EBNA-1 seropositive and 30 EBV EBNA-1 seronegative pediatric-onset MS (POMS) patients, along with 578 matched controls. CNS specific antibodies were significantly more prevalent in EBV EBNA-1 seropositive POMS patients (92.2%) than in EBV EBNA-1 seropositive controls (56.3%, P < 0.0001). However, high CNS specific antibody levels were also found in 56.6% of EBV EBNA-1 seronegative POMS patients and 17.4% of EBV EBNA-1 seronegative controls. These findings suggest that while EBV infection amplifies CNS specific autoimmune responses, high-level CNS autoreactive autoimmune responses can also occur independently of EBV EBNA-1. We further evaluated why only some individuals with high-level CNS autoreactive antibody titers develop MS. Mechanistically, we demonstrate that autoreactive immune responses are effectively controlled by NKG2C + and NKG2D + natural killer (NK) cells. These findings indicate that CNS-specific autoimmunity and impaired NK cell regulation, rather than EBV alone, are central to MS risk.

25 May 2026 in Journal of Innate Immunity
Verified
Journal Article
Open access
SBSarah M. Berger
Sarah M. Berger
LKLaura M. Kühner
Laura M. Kühner
ISInes M. Schwarzinger
Ines M. Schwarzinger
VSVerena Heiss Spornberger
Verena Heiss Spornberger
PJPeter Jaksch
Peter Jaksch
HVHannes Vietzen
Hannes Vietzen
Introduction: Progression to end-stage lung diseases is influenced by both environmental and genetic factors, yet predictive markers remain limited. The CD32-131H>R polymorphism in the FCGR2A gene alters the affinity of the FcγRIIa receptor for IgG and may impair immune clearance, potentially influencing immune responses involved in chronic lung disease. In our study, we investigated the association between the CD32-131H>R polymorphism and end-stage pulmonary diseases requiring LTX. Methods: The CD32-131H>R polymorphism was determined in 985 lung transplant recipients and 2,116 matched controls via TaqMan genotyping assays. Results: The low-affinity CD32-131R allele was significantly more prevalent among lung transplant recipients with chronic obstructive pulmonary disease (COPD) and interstitial lung diseases (ILD) compared to controls (p<0.0001 and p=0.01, respectively). Conclusion: Our study demonstrates that the CD32-131R allele is enriched among patients with end-stage COPD and ILD requiring LTX, highlighting a possible association between Fcγ receptor-mediated immune responses and end-stage pulmonary disease.